openPR Logo
Press release

New Report: Hyperlipidemia Drug Market 2019 Size, Growth Analysis Report, Forecast to 2025

09-14-2021 09:25 AM CET | Health & Medicine

Press release from: Orion Market Reports

The global hyperlipidemia drug market is estimated to witness significant growth during the forecast period. The demand for a statin to manage cholesterol is driving the market growth across the globe. This drug supports lowering cholesterol, hence reduce the chances of cardiovascular diseases, stroke, and diabetes. Statins are used to manage the plaque on blood vessels and reduce the risk of blood clots. There are various statins options are available in the market for lowering cholesterol levels. Some of the statins used in the US include Atorvastatin (Lipitor), Lovastatin (Altoprev), Pitavastatin (Livalo, Zypitamag), Pravastatin (Pravachol), Rosuvastatin (Crestor, Ezallor), and Simvastatin (Zocor).

(Get 15% Discount on Buying this Report)
Get Report Sample Copy @

Further, according to the American Heart Association (AHA), historical data shows 79.8% of adults who were at least 40 years old use of statins for lowering cholesterol from 2002 to 2013 studies. Such an extensive rise in the number of statinusers is driving the growth of the hyperlipidemia drug market. However, increasing side effects associated withstatin drugs is expected to hinder the growth of the statin drug market. Statins drugs have side effects and some patients are unable to bear it. For instance, atorvastatin and rosuvastatin are high-intensity statins which cause rare side effects like new-onset diabetes and muscle symptoms.

A Full Report of Global IoT Sensors Market is Available at:

Hence, the demand for non-statin drugs is expected to contribute to hyperlipidemia drug market growth in the near future. In 2020, the FDA has approved two non-statin drugs after a long period of the last 2 decades. For instance, in February 2020, The FDA approved the first non-statin oral medication for high cholesterol commercialized in the US and around the world. The drug, bempedoic acid, is the first in a new class of drugs to treat low-density-lipoprotein cholesterol.

Further, in February 2020, Esperion Therapeutics Inc received FDA approval for its Nexletol, a new type of cholesterol-lowering drug. This drug will help people manage their high cholesterol and reduce the risk of heart diseases. Further, other non-statin drugs for lowering cholesterol include PCSK9-targeting drugs such as Amgen’s Repatha (evolocumab), Sanofi’s Praluent (alirocumab) and inclisiran, developed by Alnylam Pharmaceuticals and The Medicines Company and currently under FDA review.

Global Hyperlipidemia Drug Market Segmentation

By Drug Class
• HMG-CoA Reductase Inhibitors (Statins)
• PCSK9 Inhibitors
• Cholesterol Absorption Inhibitors
• Fabric Acid Derivatives (Fibrates)
• Niacin (Nicotinic Acid)
• Bile Acid Sequestrants (BAS)
• Combination Therapy and Compliance
• Others

Global Hyperlipidemia Drug Market Segmentation by region

North America
• United States
• Canada

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

• China
• Japan
• India
• Rest of the Asia-Pacific

Rest of the World
• Middle East & Africa
• Latin America

Company Profiles
• Abbott Laboratories
• Amgen, Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Co.
• Daiichi Sankyo Co., Ltd.
• Dr.Reddy's Laboratories, Ltd.
• GlaxoSmithKline PLC

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Contact no: +91 780-304-0404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Report: Hyperlipidemia Drug Market 2019 Size, Growth Analysis Report, Forecast to 2025 here

News-ID: 2391671 • Views: 118

More Releases from Orion Market Reports

Smart Blood Glucose Monitors Market Analysis, Size, Current Scenario and Future …
Smart blood glucose monitor market is expected to grow at a CAGR of 7.5% from 2023 to 2029. The growth in this market can be attributed to the increasing prevalence of diabetes, technological advancements in blood glucose monitoring devices, and growing demand for home care settings. Important changes in the business allow key players to attain larger profits. This Smart Blood Glucose Monitors Market study report is the best way to
Sliding Bearing Market to Signify Strong Growth by 2023-2029
Slide bearings market is projected to grow from USD 1.02 Billion in 2017 to USD 1.48 Billion by 2029, at a CAGR of 4.5% from 2017 to 2029. The growth of the global slide bearings market can be attributed to the increasing demand for automobiles and aircraft and rising investments in infrastructure development projects across the globe. Important changes in the business allow key players to attain larger profits. This Sliding
Oil and Gas Pipeline Leak Detection System Market Sluggish Growth Rate Foreseen …
Oil and gas pipeline leak detection system sales market is expected to grow from USD 1.02 Billion in 2022 to USD 2.06 Billion by 2029, at a CAGR of 7.5% from 2022 to 2029. The growth of the market can be attributed to the increasing demand for oil and gas across the globe and the need for safety measures against pipeline leaks. Important changes in the business allow key players to
Petroleum Catalyst Market Booming Worldwide with Latest Trend and Future Scope b …
Petroleum catalyst market is expected to grow at a CAGR of 5% by 2023-2029. The growth of the market can be attributed to the increasing demand for petroleum products, especially in developing countries. Asia Pacific is expected to be the fastest-growing region during the forecast period. The global petroleum catalyst sales market can be segmented based on type, application, and region. Important changes in the business allow key players to attain

All 5 Releases

More Releases for FDA

FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding